### FORM 4

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)														
1. Name and Address of Reporting Person *- Miller Robert E				2. Issuer Name and Ticker or Trading Symbol Sonoma Pharmaceuticals, Inc. [SNOA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 07/20/2018						Year)	X Officer (give title below) Other (specify below)  Chief Financial Officer					
(Street) PETALUMA, CA 94954				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities						e Securities	Acquired, Disposed of, or Beneficially Owned					
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year		ion E	Date, if		. 8)	(A) or	Disposed o 3, 4 and 5)  (A) or (D)	f (D) Owr Tran			ed	Ownership Form:	Beneficial Ownership
	Conversion		3A. Deemed Execution Date, i	4. f Transac	ts, ca	5. Num of	rants,	form uired, Disposition, options, of the Expiration	posed conver xercisa n Date		ficially Owties) 7. Title an Amount o	ned	8. Price of Derivative	9. Number Derivative	of 10. Ownersh	
Security (Instr. 3)	or Exercise Price of Derivative Security	(Month/Day/Year)	any (Month/Day/Year)	(Instr. 8) So A (A (A (A (I)))		Derivat Securit Acquir (A) or Dispos (D) (Instr. 3	ies ed ed of	(Month/Day/Year)		ar)	Underlying Securities (Instr. 3 and 4)		Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Security Direct (I or Indire	(Instr. 4)
				Code	V	and 5) (A)	(D)	Date Exercisab		xpiration late	Title	Amount or Number of Shares				
Stock option (right to buy)	\$ 2.41	07/20/2018		A		67,733	3	07/20/20	018 0	7/20/2028	Common Stock	67,733	<u>(1)</u>	209,071	D	
Repor	ting O	wners				Rela	tions	hips								

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Miller Robert E C/O SONOMA PHARMACEUTICALS, INC. 1129 N. MCDOWELL BLVD. PETALUMA, CA 94954			Chief Financial Officer				

### **Signatures**

/s/ Robert E. Miller	07/24/2018
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The options were awarded and granted to Mr. Miller as a bonus for fiscal year 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.